During conversion of N-methoxycarbonyl-L-tert-leucine to the corresponding Weinreb amide, the carboxylic acid is preactivated with 1,1’-carbonyldiimidazole in tetrahydrofuran at a jacket setpoint of -5°C before N,O-dimethylhydroxylamine hydrochloride is introduced. The molar addition ratio is maintained at 1.00 mol MOC-L-tert-leucine to 1.05 mol CDI to 1.20 mol N,O-dimethylhydroxylamine hydrochloride, with N-methylmorpholine fixed at 1.30 mol; raising the N-methylmorpholine charge above 1.50 mol accelerates cleavage of the carbamate protecting group and produces an unacceptably high free amine byproduct. The reactor is charged with 8 volumes of THF per mass of acid, the CDI is added in three equal portions over 30 min, and the resulting imidazolide is aged for 45 min until gas evolution drops below 0.1 L/min. The hydrochloride salt is then slurried in 2 volumes of 1-methyl-2-pyrrolidone and metered in over 90 min while the internal temperature is held at 0°C to 10°C. After an 8 h hold, the batch is quenched into 10% w/w citric acid, extracted with methyl tert-butyl ether, washed with 5% sodium bicarbonate, and concentrated below 45°C at 50 mbar. The crude amide is crystallized from n-heptane and isolated on a bottom-discharge centrifuge with a 0.5 mm filtrate screen. Quality release follows ICH Q7 Chapter 11.10 for laboratory controls and USP ⟨467⟩ for residual solvents, with THF not exceeding 720 ppm, 1-methyl-2-pyrrolidone not exceeding 530 ppm, and n-heptane not exceeding 5000 ppm. The terminal product types from this sequence are N-methoxy-N-methyl amide intermediates that are further reduced under low-temperature hydride conditions to peptide aldehyde intermediates for antiviral and oncology peptide lead compounds.

Production records from 2000 L glass-lined campaigns show that the principal batch-to-batch variance arises from moisture ingress during CDI charging. When the nitrogen purge is interrupted, residual water converts CDI to imidazole and stalls preactivation, leaving unreacted starting material above 0.5 area%. Operators must verify that the purge rate is at least 0.5 vvm and that the manway is closed before the first solid charge is introduced. The material should not be combined with primary amine buffers during workup because the methoxycarbonyl group is hydrolytically unstable above pH 9.5 at 25°C; quench pH is therefore kept below 7.0, and the product is dried at 35°C under vacuum for 12 h before storage at 2–8°C.

What Limits Acylation Yield When the P2 Fragment Contains a Hindered Secondary Alcohol?

Published routes to HIV-1 protease inhibitor APIs use N-methoxycarbonyl-L-tert-leucine as the N-terminal P2 capping residue for amino alcohol intermediates in which the hydroxyl group is positioned inside a sterically constrained secondary alcohol network. The recommended batch charging ratio is 1.00 mol MOC-L-tert-leucine to 1.10 mol isobutyl chloroformate to 1.20 mol N-methylmorpholine to 1.00 mol of the des-hydroxy P2 amine substrate, with tetrahydrofuran charged at 10 volumes and the reaction mass maintained at -15°C to -10°C. The acid is first dissolved in THF and cooled to -15°C; N-methylmorpholine is added over 45 min while the jacket outlet is held below -8°C, followed by isobutyl chloroformate over 90 min. Mixed anhydride aging is limited to 45–60 min, because longer aging above -8°C forms the symmetrical anhydride impurity and reduces the desired acylation conversion by 2–4 percentage points. The amino alcohol substrate is then metered as a 1.5 M solution in THF over 2 h, the batch is warmed to 0°C, and the mixture is held for 6 h. During this hold, in-process HPLC monitoring on a C18 column with UV detection at 210 nm must show the starting amino alcohol below 0.1 area% before the quench is initiated. The isolated intermediate is washed with 10% sodium chloride, concentrated, and crystallized from ethyl acetate/n-heptane in a 1:3 v/v ratio.

Compliance is governed by ICH Q7 Chapter 8.30 for in-process controls, ICH Q3C(R8) for residual THF and ethyl acetate, and ICH Q3A(R2) for related substances, with individual unknown impurities limited to 0.10% and total impurities limited to 1.0% in the isolated intermediate. Residual isobutyl chloroformate-derived carbonates are monitored as potentially reactive alkylating impurities under a site-specific risk assessment aligned with ICH M7(R2); the purge factor for the relevant methyl ester byproduct is calculated from solubility and partitioning data, and a control point of ⟨10 ppm is set in the final API. Terminal finished product types are HIV-1 protease inhibitor APIs formulated as oral solid dosage forms, where the tert-leucine carbamate function contributes to metabolic stability and the methoxycarbonyl cap is retained in the active pharmaceutical ingredient.

On a 3000 L glass-lined reactor, the most frequent deviation is a batch temperature excursion above -5°C during mixed anhydride aging; this has been observed when the cryogenic jacket was shared with a second vessel, causing delayed cooling recovery and producing a 0.7–1.0 area% symmetrical anhydride peak. Water content in the THF must be below 0.05% w/w; a single campaign with a faulty solvent line delivered 0.12% w/w water and reduced conversion by 4 percentage points. The isolated intermediate should be stored below -20°C under nitrogen if held longer than 72 h, because the carbamate is stable at 2–8°C for short periods but slowly hydrolyzes when residual moisture exceeds 0.1% w/w. Published data for this specific hindered secondary alcohol configuration are limited; the ranges above are derived from technology transfer batches and in-process chromatographic records.

When Batch Mixed Anhydride Aging Is Replaced by a 4.5-Minute Residence in a 2 mm ID Tubular Reactor

Continuous-flow protocols for MOC-L-tert-leucine activation and coupling are implemented when the same mixed anhydride chemistry is constrained by the batch aging window. In this configuration, feed solution A is prepared by dissolving 1.00 mol MOC-L-tert-leucine and 1.05 mol N-methylmorpholine per 2.0 L of THF, feed solution B contains 1.02 mol isobutyl chloroformate per 1.36 L of THF, and feed solution C contains 1.00 mol of the amine substrate in 2.2 L of THF. The three streams are combined through static mixers into a 2 mm internal diameter tubular reactor with a 12 mL hold-up volume, with flow rates of 1.00 mL/min for A, 0.85 mL/min for B, and 1.10 mL/min for C. The mixed-anhydride residence time is 4.5 min at -10°C, after which the reaction stream is quenched in-line with 10% w/w ammonium chloride at a flow rate of 2.0 mL/min. The process is controlled by an online FTIR probe measuring the carbonyl stretch of the mixed anhydride at 1810–1820 cm⁻¹; conversion is considered complete when the anhydride peak area falls below 2% of its initial value. The product stream is then separated in a continuous centrifugal extractor, and the organic phase is concentrated through a wiped-film evaporator at 40°C and 30 mbar.

Experience with this specific configuration is limited, but published technical bulletins from continuous-processing equipment manufacturers indicate that N-methylmorpholinium chloride precipitation can raise the pressure drop across the static mixer by 0.3 bar after 72 h of continuous operation. The cleaning-in-place sequence uses 0.5 M sodium hydroxide at 50°C for 30 min, followed by water-for-injection flush until the outlet conductivity falls below 1.0 µS/cm. The process is incompatible with acetonitrile as a cosolvent because the mixed anhydride partitions into the acetonitrile-rich phase and the coupling rate drops by approximately 30% relative to THF-only solvent. Process validation follows ICH Q7 Chapter 12.50, and equipment verification is performed under ASTM E2500 for specification, design, and verification of pharmaceutical manufacturing systems. Terminal finished product types are solution-phase peptide fragments destined for later final deprotection and lyophilization into peptide APIs for injectable or oral delivery.

Chiral auxiliary synthesis from N-methoxycarbonyl-L-tert-leucine follows a different downstream route: reduction to the corresponding amino alcohol and ring closure to 4-tert-butyl-2-oxazolidinone. The first charge ratio is 1.00 mol MOC-L-tert-leucine to 1.25 mol borane-dimethyl sulfide complex in 6 volumes of THF at 0°C, with methanol used as the quench agent at 2.0 mol per mol of borane after 12 h at 25°C. The isolated amino alcohol is then dissolved in 8 volumes of dichloromethane, and 3.00 mol of triethylamine is added before 0.35 mol of triphosgene is metered as a solution over 2 h at 0°C to 5°C. The ring-closure stream is washed with 1 N HCl, dried over magnesium sulfate, and distilled to an oil that is crystallized from ethyl acetate/n-heptane. Published data for this exact reduction sequence using N-methoxycarbonyl protection is limited; the borane charge must therefore be confirmed in development batches because excess borane can attack the carbamate carbonyl and generate N-methylated byproducts. Compliance for organocatalyst-grade material is managed under REACH 1907/2006 Article 6 for annual tonnage registration and, when the auxiliary is later used in a drug substance synthesis, the isolated intermediate is controlled under ICH Q7 Chapter 7.30 for storage and requalification. Terminal product types are 4-tert-butyl-2-oxazolidinone auxiliaries used in asymmetric aldol and conjugate addition reactions to prepare single-enantiomer building blocks for pharmaceutical synthesis.

Residual Water and Carbamate Cleavage in 5000 L Glass-Lined Condensation Reactors

In peptide API manufacturing campaigns where N-methoxycarbonyl-L-tert-leucine is used as the capping residue for a solution-phase peptide fragment, the process solvent is usually N,N-dimethylformamide rather than tetrahydrofuran because the downstream peptide backbone remains soluble at low temperature. The addition ratio is 3.0 mol MOC-L-tert-leucine relative to 1.0 mol of free N-terminal peptide on resin, with 3.3 mol HATU and 6.0 mol N,N-diisopropylethylamine in 8 mL DMF per gram of resin; coupling is carried out at 20°C for 12 h, with a resin sample taken for Kaiser or chloranil testing to confirm the free amine is below the detection limit. Following cleavage with 95% TFA / 2.5% water / 2.5% triisopropylsilane, the fragment is purified by preparative C18 HPLC using 0.1% TFA in water/acetonitrile and lyophilized. Compliance for the peptide API stage includes ICH Q7 Chapter 8 production controls, ICH Q3C(R8) for residual acetonitrile and DMF, and Ph. Eur. 2.2.46 or USP ⟨621⟩ for chromatographic separation. Terminal finished product types are therapeutic peptide APIs for injection, where the tert-leucine residue at the N-terminus reduces exopeptidase degradation and extends plasma half-life in preclinical pharmacokinetic studies.